NICE has recommended Almirall’s Ilumetri and UCB’s Cimzia as treatment options for severe plaque psoriasis in final draft guidelines.
News
Roche and Genentech take global macular degeneration step
Roche and Genentech have initiated two large global Phase III clinical trials testing the potential of faricimab in wet age-related macular degeneration.
Positive results for monthly HIV drug
Johnson & Johnson/ViiV’s once-monthly, injectable drug combination for HIV shows comparable efficacy to daily oral treatment in two trials.
Darolutamide submitted for EU approval
Orion Corporation and Bayer have submitted a marketing application in Europe for use of darolutamide in patients with a certain type of prostate cancer.
Study shows reduced hypoglycaemia after switch to Tresiba
Novo Nordisk’s Tresiba has been found to be efficient in treating diabetes compared to other basal insulins.
FDA grants Dupixent Priority Review for sinusitis
US regulators have accepted Sanofi’s Dupixent for Priority Review as a treatment for rhinosinusitis with nasal polyps.
NICE updates high blood pressure guidelines
NICE has published a draft updated guideline on the diagnosis and management of high blood pressure, with thousands more patients to qualify for treatment.
EMA validates Bavencio for review in advanced RCC
European regulators have validated Merck’s application Bavencio for review in kidney cancer.
32 cases of measles confirmed in Greater Manchester
Public health officials having confirmed a sharp rise of measles across Greater Manchester, leading to renewed calls for the public to ensure they are fully vaccinated against the disease.
Campaigners call for NHS access to Orkambi as MP inquiry gets underway
Patients and campaigners took to the streets in London yesterday demanding NHS access to Vertex’ cystic fibrosis drugs, following a public hearing on the situation ordered by MPs.
Allergan’s rapastinel fails to hit key targets in depression trials
Allergan’s rapastinel has failed to hit its primary endpoints in three late-stage studies assessing its potential as an adjunctive treatment for depression.
Vertex’ three-drug CF combo hits PhIII targets
Vertex’ three-drug cystic fibrosis regimen – combining the investigational next-generation corrector VX-445 with Kalydeco (ivacaftor) and tezacaftor – has achieved primary endpoints of two Phase III studies in patients the condition.
86% of Britain believe NHS faces a ‘major’ funding problem
Most people feel the NHS has a major funding problem, according to the 2018 British Social Attitudes (BSA) survey.
Researchers develop new prognostic test for colorectal cancer
High-risk stage two cancer patients could be identified more easily and accurately, due to a hopeful new prognostic method developed by researchers at the University of St Andrews.
FDA approves nasal spray for treatment-resistant depression
The FDA has approved Johnson & Johnson’s Spravato for treatment-resistant depression, offering patients the first new treatment option in several years.
